| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Schizophrenia | 10 | 2024 | 91 | 2.940 |
Why?
|
| Cardiomegaly | 10 | 2011 | 43 | 2.080 |
Why?
|
| Heart | 6 | 2019 | 181 | 1.230 |
Why?
|
| Myocytes, Cardiac | 9 | 2019 | 173 | 1.210 |
Why?
|
| Ethanol | 4 | 2015 | 221 | 1.190 |
Why?
|
| Myocardium | 6 | 2014 | 251 | 1.140 |
Why?
|
| Psychotic Disorders | 3 | 2023 | 69 | 1.110 |
Why?
|
| Depression | 3 | 2024 | 837 | 1.100 |
Why?
|
| Myocardial Contraction | 6 | 2015 | 46 | 1.020 |
Why?
|
| Angiotensin II | 4 | 2011 | 103 | 0.970 |
Why?
|
| Insulin-Like Growth Factor I | 5 | 2014 | 81 | 0.880 |
Why?
|
| Somatoform Disorders | 1 | 2024 | 17 | 0.870 |
Why?
|
| Cross-Sectional Studies | 14 | 2024 | 3077 | 0.780 |
Why?
|
| Captopril | 3 | 2011 | 6 | 0.770 |
Why?
|
| Lebanon | 12 | 2024 | 20 | 0.770 |
Why?
|
| Heart Rate | 2 | 2014 | 261 | 0.760 |
Why?
|
| Overnutrition | 1 | 2022 | 6 | 0.750 |
Why?
|
| Bipolar Disorder | 2 | 2019 | 83 | 0.730 |
Why?
|
| Caloric Restriction | 1 | 2022 | 34 | 0.730 |
Why?
|
| Heart Failure | 4 | 2019 | 298 | 0.700 |
Why?
|
| Mitogen-Activated Protein Kinases | 3 | 2014 | 136 | 0.690 |
Why?
|
| Signal Transduction | 11 | 2021 | 2111 | 0.640 |
Why?
|
| Male | 35 | 2024 | 22779 | 0.630 |
Why?
|
| Humans | 45 | 2025 | 42163 | 0.620 |
Why?
|
| Potassium Channels | 2 | 2010 | 81 | 0.590 |
Why?
|
| Proto-Oncogene Proteins c-akt | 6 | 2014 | 297 | 0.580 |
Why?
|
| Patient Readmission | 1 | 2019 | 120 | 0.560 |
Why?
|
| Myocardial Reperfusion Injury | 2 | 2015 | 51 | 0.540 |
Why?
|
| Alcoholism | 2 | 2018 | 292 | 0.530 |
Why?
|
| Psychometrics | 4 | 2024 | 350 | 0.530 |
Why?
|
| Neurosurgery | 1 | 2016 | 4 | 0.520 |
Why?
|
| Stress Disorders, Post-Traumatic | 1 | 2024 | 547 | 0.520 |
Why?
|
| Air Pollutants | 1 | 2018 | 127 | 0.510 |
Why?
|
| Rats | 14 | 2015 | 3701 | 0.510 |
Why?
|
| Hallucinations | 4 | 2023 | 11 | 0.510 |
Why?
|
| Capillaries | 1 | 2015 | 27 | 0.460 |
Why?
|
| Cardiotonic Agents | 2 | 2013 | 39 | 0.450 |
Why?
|
| Thrombotic Microangiopathies | 1 | 2014 | 2 | 0.450 |
Why?
|
| Cyclic AMP-Dependent Protein Kinases | 3 | 2010 | 74 | 0.450 |
Why?
|
| Oxidative Stress | 3 | 2018 | 990 | 0.440 |
Why?
|
| Coronary Vessels | 1 | 2015 | 92 | 0.440 |
Why?
|
| Microvessels | 1 | 2014 | 31 | 0.440 |
Why?
|
| Exercise | 2 | 2022 | 674 | 0.420 |
Why?
|
| Protein Kinase C | 2 | 2004 | 124 | 0.410 |
Why?
|
| Cardiomyopathy, Alcoholic | 1 | 2013 | 1 | 0.410 |
Why?
|
| Calcitonin Gene-Related Peptide | 1 | 2013 | 11 | 0.400 |
Why?
|
| Oxygen Consumption | 1 | 2013 | 111 | 0.400 |
Why?
|
| Rats, Sprague-Dawley | 9 | 2013 | 1737 | 0.400 |
Why?
|
| Nitrates | 1 | 2013 | 63 | 0.390 |
Why?
|
| Central Nervous System Depressants | 1 | 2013 | 42 | 0.390 |
Why?
|
| Animals | 23 | 2021 | 16695 | 0.390 |
Why?
|
| Endothelium, Vascular | 1 | 2014 | 261 | 0.380 |
Why?
|
| RNA, Messenger | 1 | 2017 | 1265 | 0.380 |
Why?
|
| Biomedical Research | 3 | 2025 | 467 | 0.370 |
Why?
|
| Cardiomyopathies | 2 | 2019 | 63 | 0.370 |
Why?
|
| Delayed Rectifier Potassium Channels | 1 | 2011 | 1 | 0.360 |
Why?
|
| Dietary Supplements | 1 | 2013 | 208 | 0.360 |
Why?
|
| Child Abuse | 2 | 2023 | 90 | 0.360 |
Why?
|
| Reproducibility of Results | 3 | 2024 | 1058 | 0.350 |
Why?
|
| Female | 18 | 2024 | 24018 | 0.350 |
Why?
|
| Calcium Channels, L-Type | 1 | 2011 | 20 | 0.350 |
Why?
|
| Cardiomyopathy, Dilated | 2 | 2008 | 30 | 0.350 |
Why?
|
| Potassium Channels, Inwardly Rectifying | 1 | 2011 | 63 | 0.350 |
Why?
|
| Psychiatric Status Rating Scales | 2 | 2023 | 280 | 0.330 |
Why?
|
| Sex Characteristics | 2 | 2013 | 253 | 0.330 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2008 | 310 | 0.320 |
Why?
|
| Receptor Cross-Talk | 1 | 2010 | 18 | 0.320 |
Why?
|
| Haloperidol | 2 | 2021 | 36 | 0.320 |
Why?
|
| Anxiety | 3 | 2024 | 847 | 0.310 |
Why?
|
| Chlorpromazine | 3 | 2023 | 6 | 0.290 |
Why?
|
| Alcohol-Induced Disorders | 1 | 2008 | 2 | 0.290 |
Why?
|
| Apoptosis | 6 | 2015 | 1541 | 0.280 |
Why?
|
| Adult | 10 | 2024 | 13458 | 0.270 |
Why?
|
| Collagen Type IV | 2 | 2021 | 48 | 0.270 |
Why?
|
| Meningeal Neoplasms | 2 | 2022 | 6 | 0.270 |
Why?
|
| Meningioma | 2 | 2022 | 8 | 0.260 |
Why?
|
| Delusions | 2 | 2023 | 8 | 0.250 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 2 | 2004 | 78 | 0.250 |
Why?
|
| Atrial Function, Left | 1 | 2005 | 3 | 0.240 |
Why?
|
| Gene Transfer Techniques | 1 | 2006 | 53 | 0.240 |
Why?
|
| Quality of Life | 2 | 2022 | 599 | 0.240 |
Why?
|
| Young Adult | 7 | 2024 | 4936 | 0.230 |
Why?
|
| Receptors, CXCR4 | 2 | 2019 | 74 | 0.230 |
Why?
|
| Interinstitutional Relations | 1 | 2025 | 51 | 0.230 |
Why?
|
| Sirolimus | 3 | 2023 | 70 | 0.220 |
Why?
|
| Catechol O-Methyltransferase | 1 | 2024 | 18 | 0.220 |
Why?
|
| Atrial Function | 1 | 2004 | 1 | 0.220 |
Why?
|
| Upper Extremity Deformities, Congenital | 1 | 2024 | 1 | 0.220 |
Why?
|
| Adolescent | 4 | 2024 | 5950 | 0.220 |
Why?
|
| Economic Recession | 1 | 2024 | 1 | 0.220 |
Why?
|
| Phosphorylation | 6 | 2014 | 973 | 0.210 |
Why?
|
| Minority Groups | 2 | 2021 | 663 | 0.210 |
Why?
|
| Disease Models, Animal | 6 | 2019 | 1554 | 0.210 |
Why?
|
| Off-Label Use | 1 | 2023 | 4 | 0.210 |
Why?
|
| Speech | 1 | 2023 | 16 | 0.200 |
Why?
|
| Adaptation, Physiological | 1 | 2004 | 135 | 0.200 |
Why?
|
| Angiotensin I | 1 | 2003 | 5 | 0.200 |
Why?
|
| Cooperative Behavior | 1 | 2025 | 250 | 0.200 |
Why?
|
| Renin-Angiotensin System | 1 | 2003 | 44 | 0.200 |
Why?
|
| Cocaine | 1 | 2005 | 248 | 0.190 |
Why?
|
| Nicotine | 1 | 2005 | 290 | 0.190 |
Why?
|
| Skull Base Neoplasms | 1 | 2022 | 2 | 0.190 |
Why?
|
| Calcium Signaling | 2 | 2013 | 108 | 0.190 |
Why?
|
| Kidney Glomerulus | 2 | 2014 | 85 | 0.190 |
Why?
|
| Parent-Child Relations | 1 | 2023 | 125 | 0.180 |
Why?
|
| NF-kappa B | 3 | 2014 | 355 | 0.180 |
Why?
|
| Cognition Disorders | 1 | 2023 | 243 | 0.180 |
Why?
|
| Middle Aged | 8 | 2024 | 11819 | 0.180 |
Why?
|
| Heart Ventricles | 2 | 2015 | 123 | 0.180 |
Why?
|
| Nephritis, Hereditary | 1 | 2021 | 15 | 0.180 |
Why?
|
| Perinatology | 1 | 2020 | 6 | 0.170 |
Why?
|
| Anti-Glomerular Basement Membrane Disease | 1 | 2021 | 25 | 0.170 |
Why?
|
| Truth Disclosure | 1 | 2020 | 26 | 0.170 |
Why?
|
| Fetus | 1 | 2020 | 101 | 0.170 |
Why?
|
| Health Care Surveys | 1 | 2020 | 152 | 0.170 |
Why?
|
| Aging | 1 | 2005 | 764 | 0.160 |
Why?
|
| Antipsychotic Agents | 1 | 2021 | 81 | 0.160 |
Why?
|
| Patch-Clamp Techniques | 2 | 2011 | 228 | 0.160 |
Why?
|
| Homeostasis | 2 | 2013 | 193 | 0.160 |
Why?
|
| Time Factors | 5 | 2013 | 1848 | 0.160 |
Why?
|
| Prevalence | 3 | 2019 | 1597 | 0.160 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2024 | 860 | 0.160 |
Why?
|
| Alcohol Drinking | 2 | 2015 | 585 | 0.160 |
Why?
|
| Efficiency | 1 | 2019 | 14 | 0.160 |
Why?
|
| Mice, Knockout | 4 | 2019 | 1010 | 0.150 |
Why?
|
| Salvia | 1 | 2018 | 10 | 0.150 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 2 | 2010 | 105 | 0.150 |
Why?
|
| Cell Physiological Phenomena | 1 | 2018 | 9 | 0.140 |
Why?
|
| Chlorophyll | 1 | 2018 | 24 | 0.140 |
Why?
|
| Pigments, Biological | 1 | 2018 | 18 | 0.140 |
Why?
|
| Hallucinogens | 1 | 2018 | 29 | 0.140 |
Why?
|
| Photosynthesis | 1 | 2018 | 34 | 0.140 |
Why?
|
| Ascorbic Acid | 1 | 2018 | 74 | 0.140 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2006 | 744 | 0.140 |
Why?
|
| Motor Skills | 1 | 2018 | 45 | 0.140 |
Why?
|
| Plant Leaves | 1 | 2018 | 134 | 0.140 |
Why?
|
| Blotting, Western | 2 | 2011 | 884 | 0.130 |
Why?
|
| Air Pollution | 1 | 2018 | 87 | 0.130 |
Why?
|
| Comorbidity | 1 | 2019 | 725 | 0.130 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2018 | 385 | 0.130 |
Why?
|
| Cardiovascular System | 1 | 2017 | 37 | 0.130 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2017 | 106 | 0.130 |
Why?
|
| Ecosystem | 1 | 2018 | 171 | 0.130 |
Why?
|
| Anxiety Disorders | 1 | 2020 | 319 | 0.130 |
Why?
|
| Dyslipidemias | 1 | 2017 | 48 | 0.130 |
Why?
|
| History, 21st Century | 1 | 2016 | 85 | 0.130 |
Why?
|
| Endothelial Cells | 3 | 2014 | 324 | 0.130 |
Why?
|
| Environmental Monitoring | 1 | 2018 | 226 | 0.130 |
Why?
|
| History, 20th Century | 1 | 2016 | 124 | 0.130 |
Why?
|
| Perception | 1 | 2018 | 209 | 0.120 |
Why?
|
| Vascular Endothelial Growth Factor A | 2 | 2014 | 180 | 0.120 |
Why?
|
| Depressive Disorder, Major | 1 | 2018 | 128 | 0.120 |
Why?
|
| Mutation | 1 | 2021 | 1169 | 0.120 |
Why?
|
| Diet | 1 | 2022 | 810 | 0.120 |
Why?
|
| Water | 1 | 2018 | 314 | 0.120 |
Why?
|
| Ventricular Function, Left | 2 | 2013 | 111 | 0.120 |
Why?
|
| Heart Atria | 2 | 2005 | 28 | 0.120 |
Why?
|
| Public Opinion | 1 | 2014 | 20 | 0.110 |
Why?
|
| Mice | 6 | 2021 | 6490 | 0.110 |
Why?
|
| Child | 4 | 2024 | 3381 | 0.110 |
Why?
|
| Congresses as Topic | 1 | 2014 | 49 | 0.110 |
Why?
|
| Rats, Transgenic | 1 | 2014 | 31 | 0.110 |
Why?
|
| Chromosome Breakpoints | 1 | 2014 | 1 | 0.110 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2014 | 59 | 0.110 |
Why?
|
| Gene Expression Profiling | 2 | 2008 | 683 | 0.110 |
Why?
|
| Habits | 1 | 2014 | 8 | 0.110 |
Why?
|
| Morpholines | 1 | 2014 | 73 | 0.110 |
Why?
|
| Chromones | 1 | 2014 | 53 | 0.110 |
Why?
|
| Language Development Disorders | 1 | 2014 | 14 | 0.100 |
Why?
|
| Cell Survival | 2 | 2014 | 934 | 0.100 |
Why?
|
| Superoxide Dismutase | 1 | 2014 | 158 | 0.100 |
Why?
|
| Sarcomeres | 1 | 2013 | 8 | 0.100 |
Why?
|
| Enzyme Activation | 1 | 2014 | 462 | 0.100 |
Why?
|
| Inflammation Mediators | 1 | 2014 | 138 | 0.100 |
Why?
|
| Schizophrenic Psychology | 2 | 2024 | 16 | 0.100 |
Why?
|
| Developmental Disabilities | 1 | 2014 | 66 | 0.100 |
Why?
|
| Alcoholic Beverages | 1 | 2013 | 16 | 0.100 |
Why?
|
| Cross-Over Studies | 1 | 2013 | 112 | 0.100 |
Why?
|
| Exercise Test | 1 | 2013 | 75 | 0.100 |
Why?
|
| Nitric Oxide | 2 | 2013 | 381 | 0.100 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2014 | 1112 | 0.100 |
Why?
|
| Sleep Initiation and Maintenance Disorders | 1 | 2014 | 70 | 0.100 |
Why?
|
| Retrospective Studies | 1 | 2019 | 2485 | 0.100 |
Why?
|
| Cell Separation | 1 | 2013 | 94 | 0.100 |
Why?
|
| Ischemic Preconditioning | 1 | 2013 | 49 | 0.100 |
Why?
|
| France | 2 | 2024 | 21 | 0.100 |
Why?
|
| Gonadal Steroid Hormones | 1 | 2013 | 53 | 0.100 |
Why?
|
| Ventricular Remodeling | 1 | 2013 | 58 | 0.100 |
Why?
|
| Progesterone | 1 | 2013 | 120 | 0.100 |
Why?
|
| Myocardial Ischemia | 1 | 2013 | 82 | 0.100 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2013 | 100 | 0.100 |
Why?
|
| Guanine Nucleotide Exchange Factors | 1 | 2012 | 33 | 0.100 |
Why?
|
| Muscle, Skeletal | 1 | 2015 | 308 | 0.100 |
Why?
|
| Stroke Volume | 1 | 2013 | 122 | 0.090 |
Why?
|
| Fibronectins | 1 | 2012 | 69 | 0.090 |
Why?
|
| Research Personnel | 2 | 2025 | 191 | 0.090 |
Why?
|
| Inpatients | 2 | 2023 | 78 | 0.090 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 1 | 2011 | 32 | 0.090 |
Why?
|
| Vitamin D Deficiency | 1 | 2013 | 107 | 0.090 |
Why?
|
| Cell Adhesion | 1 | 2012 | 237 | 0.090 |
Why?
|
| Estrogens | 1 | 2013 | 202 | 0.090 |
Why?
|
| Nitric Oxide Synthase Type III | 1 | 2011 | 74 | 0.090 |
Why?
|
| Neurologic Examination | 2 | 2023 | 30 | 0.090 |
Why?
|
| Estradiol | 1 | 2013 | 269 | 0.090 |
Why?
|
| Peptide Fragments | 1 | 2013 | 301 | 0.090 |
Why?
|
| Kidney Diseases | 1 | 2013 | 170 | 0.090 |
Why?
|
| Receptors, Adrenergic, beta-2 | 1 | 2010 | 19 | 0.080 |
Why?
|
| Vitamin D | 1 | 2013 | 196 | 0.080 |
Why?
|
| Substance-Related Disorders | 1 | 2018 | 825 | 0.080 |
Why?
|
| Promethazine | 2 | 2021 | 4 | 0.080 |
Why?
|
| Psychomotor Agitation | 2 | 2021 | 8 | 0.080 |
Why?
|
| Calcium | 1 | 2013 | 487 | 0.080 |
Why?
|
| Abdominal Neoplasms | 1 | 2009 | 3 | 0.080 |
Why?
|
| Gene Expression Regulation | 2 | 2019 | 1066 | 0.070 |
Why?
|
| Cognition | 2 | 2023 | 458 | 0.070 |
Why?
|
| Sarcoplasmic Reticulum Calcium-Transporting ATPases | 1 | 2008 | 8 | 0.070 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 1 | 2008 | 103 | 0.070 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 1 | 2008 | 100 | 0.070 |
Why?
|
| Membrane Potentials | 1 | 2008 | 221 | 0.070 |
Why?
|
| Students | 1 | 2014 | 617 | 0.070 |
Why?
|
| Organ Specificity | 1 | 2008 | 141 | 0.070 |
Why?
|
| Cells, Cultured | 4 | 2015 | 1617 | 0.070 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2008 | 159 | 0.070 |
Why?
|
| Rats, Inbred OLETF | 1 | 2006 | 5 | 0.060 |
Why?
|
| Sarcoplasmic Reticulum | 1 | 2006 | 7 | 0.060 |
Why?
|
| Calcium-Transporting ATPases | 1 | 2006 | 13 | 0.060 |
Why?
|
| Cardiovascular Diseases | 1 | 2013 | 729 | 0.060 |
Why?
|
| Isoproterenol | 2 | 2019 | 38 | 0.060 |
Why?
|
| Multivariate Analysis | 2 | 2019 | 638 | 0.060 |
Why?
|
| Protein Kinases | 1 | 2005 | 100 | 0.060 |
Why?
|
| Toll-Like Receptor 4 | 1 | 2005 | 64 | 0.060 |
Why?
|
| Adrenergic alpha-Agonists | 1 | 2004 | 34 | 0.050 |
Why?
|
| Norepinephrine | 1 | 2004 | 110 | 0.050 |
Why?
|
| Upper Extremity | 1 | 2024 | 15 | 0.050 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2005 | 206 | 0.050 |
Why?
|
| Prenatal Exposure Delayed Effects | 1 | 2005 | 188 | 0.050 |
Why?
|
| Cluster Analysis | 1 | 2024 | 206 | 0.050 |
Why?
|
| Severity of Illness Index | 2 | 2022 | 708 | 0.050 |
Why?
|
| Divorce | 1 | 2023 | 7 | 0.050 |
Why?
|
| Risk Factors | 2 | 2024 | 3942 | 0.050 |
Why?
|
| Patients | 1 | 2023 | 16 | 0.050 |
Why?
|
| Cardiac Surgical Procedures | 1 | 2003 | 54 | 0.050 |
Why?
|
| Models, Biological | 1 | 2006 | 711 | 0.050 |
Why?
|
| Neovascularization, Physiologic | 2 | 2013 | 80 | 0.050 |
Why?
|
| Genotype | 1 | 2024 | 796 | 0.050 |
Why?
|
| Environmental Exposure | 1 | 2024 | 247 | 0.050 |
Why?
|
| Forkhead Transcription Factors | 2 | 2012 | 75 | 0.040 |
Why?
|
| Aggression | 1 | 2022 | 101 | 0.040 |
Why?
|
| Models, Theoretical | 1 | 2003 | 230 | 0.040 |
Why?
|
| Protein Structure, Quaternary | 1 | 2021 | 70 | 0.040 |
Why?
|
| Role Playing | 1 | 2020 | 3 | 0.040 |
Why?
|
| Longevity | 1 | 2023 | 171 | 0.040 |
Why?
|
| Hospitals, Psychiatric | 1 | 2021 | 16 | 0.040 |
Why?
|
| RNA Interference | 2 | 2012 | 246 | 0.040 |
Why?
|
| Maryland | 1 | 2021 | 61 | 0.040 |
Why?
|
| Blood Pressure | 1 | 2004 | 662 | 0.040 |
Why?
|
| Cross-Cultural Comparison | 1 | 2021 | 109 | 0.040 |
Why?
|
| Radiology | 1 | 2020 | 12 | 0.040 |
Why?
|
| United States | 2 | 2025 | 5072 | 0.040 |
Why?
|
| Ultrasonography, Prenatal | 1 | 2020 | 40 | 0.040 |
Why?
|
| Gynecology | 1 | 2020 | 33 | 0.040 |
Why?
|
| Overweight | 1 | 2023 | 248 | 0.040 |
Why?
|
| Infant | 1 | 2024 | 1143 | 0.040 |
Why?
|
| Obstetrics | 1 | 2020 | 41 | 0.040 |
Why?
|
| Protein Multimerization | 1 | 2021 | 114 | 0.040 |
Why?
|
| Neuropsychological Tests | 1 | 2021 | 281 | 0.040 |
Why?
|
| Pregnancy | 1 | 2005 | 1737 | 0.040 |
Why?
|
| Adaptation, Psychological | 1 | 2023 | 410 | 0.040 |
Why?
|
| Work | 1 | 2019 | 7 | 0.040 |
Why?
|
| Parents | 1 | 2023 | 359 | 0.040 |
Why?
|
| Sampling Studies | 1 | 2019 | 64 | 0.040 |
Why?
|
| Atrial Natriuretic Factor | 1 | 2019 | 11 | 0.040 |
Why?
|
| Receptors, Adrenergic, beta | 1 | 2019 | 35 | 0.040 |
Why?
|
| Chemokine CXCL12 | 1 | 2019 | 32 | 0.040 |
Why?
|
| Predictive Value of Tests | 1 | 2020 | 438 | 0.040 |
Why?
|
| Attitude of Health Personnel | 1 | 2020 | 222 | 0.040 |
Why?
|
| Mitochondria, Heart | 1 | 2019 | 60 | 0.040 |
Why?
|
| Hypertension | 1 | 2005 | 823 | 0.040 |
Why?
|
| Linear Models | 1 | 2019 | 311 | 0.040 |
Why?
|
| Sensitivity and Specificity | 1 | 2020 | 602 | 0.040 |
Why?
|
| Reflex, Abnormal | 1 | 2018 | 4 | 0.040 |
Why?
|
| Prospective Studies | 1 | 2022 | 1574 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2019 | 358 | 0.030 |
Why?
|
| Financing, Government | 1 | 2017 | 20 | 0.030 |
Why?
|
| Models, Molecular | 1 | 2021 | 875 | 0.030 |
Why?
|
| Memory | 1 | 2018 | 175 | 0.030 |
Why?
|
| Practice Guidelines as Topic | 1 | 2017 | 225 | 0.030 |
Why?
|
| Ribosomal Protein S6 Kinases, 70-kDa | 2 | 2005 | 11 | 0.030 |
Why?
|
| Aged | 1 | 2008 | 7982 | 0.030 |
Why?
|
| Schools, Medical | 1 | 2017 | 208 | 0.030 |
Why?
|
| Rats, Wistar | 1 | 2015 | 282 | 0.030 |
Why?
|
| Obesity | 1 | 2023 | 1131 | 0.030 |
Why?
|
| Hospitalization | 1 | 2018 | 482 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 2 | 2013 | 1804 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2018 | 1266 | 0.030 |
Why?
|
| Chromosome Inversion | 1 | 2014 | 9 | 0.030 |
Why?
|
| DNA Copy Number Variations | 1 | 2014 | 37 | 0.030 |
Why?
|
| Translocation, Genetic | 1 | 2014 | 40 | 0.030 |
Why?
|
| Pedigree | 1 | 2014 | 94 | 0.030 |
Why?
|
| Genetic Association Studies | 1 | 2014 | 118 | 0.030 |
Why?
|
| Cardiovascular Agents | 1 | 2013 | 24 | 0.030 |
Why?
|
| Adipokines | 1 | 2013 | 25 | 0.030 |
Why?
|
| Health Status Indicators | 1 | 2014 | 90 | 0.030 |
Why?
|
| Activities of Daily Living | 1 | 2014 | 136 | 0.020 |
Why?
|
| Recovery of Function | 1 | 2013 | 107 | 0.020 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2013 | 96 | 0.020 |
Why?
|
| Stem Cells | 1 | 2013 | 151 | 0.020 |
Why?
|
| Cytoskeleton | 1 | 2012 | 111 | 0.020 |
Why?
|
| Sequence Analysis, DNA | 1 | 2014 | 508 | 0.020 |
Why?
|
| Base Sequence | 1 | 2014 | 997 | 0.020 |
Why?
|
| Sleep | 1 | 2014 | 179 | 0.020 |
Why?
|
| Caspase 3 | 1 | 2012 | 226 | 0.020 |
Why?
|
| Vasodilation | 1 | 2011 | 64 | 0.020 |
Why?
|
| Transfection | 1 | 2012 | 526 | 0.020 |
Why?
|
| Pyrazoles | 1 | 2011 | 93 | 0.020 |
Why?
|
| Isoenzymes | 1 | 2011 | 169 | 0.020 |
Why?
|
| Molecular Sequence Data | 1 | 2014 | 1559 | 0.020 |
Why?
|
| Adrenergic beta-Agonists | 1 | 2010 | 27 | 0.020 |
Why?
|
| Pyrimidines | 1 | 2011 | 130 | 0.020 |
Why?
|
| Peptides | 1 | 2013 | 357 | 0.020 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2012 | 379 | 0.020 |
Why?
|
| Universities | 1 | 2014 | 539 | 0.020 |
Why?
|
| Cyclic AMP | 1 | 2010 | 135 | 0.020 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2010 | 88 | 0.020 |
Why?
|
| Cranial Irradiation | 1 | 2009 | 4 | 0.020 |
Why?
|
| Inflammation | 1 | 2014 | 729 | 0.020 |
Why?
|
| Radiosurgery | 1 | 2009 | 56 | 0.020 |
Why?
|
| Protein Binding | 1 | 2011 | 1076 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2009 | 577 | 0.020 |
Why?
|
| Thiocarbamates | 1 | 2005 | 5 | 0.010 |
Why?
|
| Myeloid Differentiation Factor 88 | 1 | 2005 | 15 | 0.010 |
Why?
|
| Pyrrolidines | 1 | 2005 | 30 | 0.010 |
Why?
|
| Organ Size | 1 | 2005 | 167 | 0.010 |
Why?
|
| Models, Animal | 1 | 2005 | 149 | 0.010 |
Why?
|
| Body Weight | 1 | 2005 | 428 | 0.010 |
Why?
|
| Mice, Transgenic | 1 | 2005 | 658 | 0.010 |
Why?
|
| Myocardial Infarction | 1 | 2005 | 242 | 0.010 |
Why?
|
| Antioxidants | 1 | 2005 | 439 | 0.010 |
Why?
|